Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant treatment after primary enucleation for extensive unilateral retinoblastoma
2009-016448-38Phase 2Active
- Sponsor
- Institut Curie
- Start
- Oct 2009
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vincristine, etoposide, cyclophosphamide and thiotepa in retinoblastoma (Rb), sponsored by Institut Curie. Primary endpoints: Overall survival and Recurrence-free survival. Started Oct 2009; status: active.
02
Drugs
vincristineetoposidecyclophosphamidethiotepa
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on 2009-016448-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016448-38.